Introduction
lyme borreliosis is the most wide-spread tick-borne infectious disease in the northern hemisphere. it is a chronic and multisystem infectious disease caused by several species of Borrelia burgdorferi sensu lato complex. three main species are known to cause the disease in europe, namely Borrelia afzelii, Borrelia garinii and Borrelia burgdorferi sensu stricto (7) . the ability to cause persistent infection in humans and a wide variety of mammalian hosts is a common property of lyme disease borrelia.
early manifestations of lyme disease include typical skin lesion erythema migrans as a sign of early localized infection, and/or unspecific flu-like symptoms, acute meningitis or meningopolyneuritis, acute arthritis, which are signs of early disseminated infection. late manifestations may appear as chronic neurological abnormalities, chronic arthritis or acrodermatitis chronica atrophicans, marking late disseminated infection (8, 9) .
Diagnosis of lyme borreliosis primarily depends on clinical signs and serological findings. the two methods most commonly used for lyme disease serology are eliSA and immunoblotting. eliSA tests using various B. burgdorferi sensu lato protein antigens have been described (ospA, ospc, Fla, Vlse). Among them, Vlse is the most sensitive diagnostic antigen with conserved immunogenic epitopes (4) .
the Vlse gene of B. burgdorferi consists of expression site (vlse) and 15 silent vls cassettes that show a high degree of homology (90 % to 96 %) with the expressed cassette, between which recombination events and reassortments occur very often. the variable section of each cassette consists of 6 variable and 6 invariable regions. the last, sixth, invariable region (iR6) is 26 amino acids long. it was shown that iR6 is immunodominant and is highly conserved among strains and genospecies of B. burgdorferi sensu lato. the authors found that igG antibodies to iR6 (c6) are readily detected in early and late stages of the disease (5, 6) . All this makes iR6 (c6) very promising for the goals of laboratory diagnosis. if c6 is highly conservative among various species of B. burgdorferi sensu lato complex, then it means that c6 might be used for testing of serum samples from patients from different geographic regions regardless of the Borrelia species of origin of c6.
We tested these two statements in practice with serum samples from Bulgarian patients with lyme disease, i.e. that c6: 1) possesses high immunogenicity, and 2) is highly conserved among species of the complex B. burgdorferi sensu lato.
Materials and Methods

Peptides
Peptides consisting of 26 amino acids were synthesized (Proteogenix SAS, France). these 26 amino acid residues correspond to iR6 regions of Vlse proteins from the three main pathogenic borrelia of the B. burgdorferi sensu lato complex causing lyme disease in europe: B. burgdorferi sensu stricto, B. garinii, and B. afzelii. two very similar peptides were synthesized from two B. burgdorferi sensu stricto strains -B31, isolated from a tick, and 297, isolated from cerebrospinal fluid of a patient with neuroborreliosis. the reason to synthesize peptides from two type strains of one species is the previously observed difference in their reactivity (5) .
the amino acid sequences of the newly synthesized peptides are shown below: C6 PePtIdes froM BORRELIA BuRgdORfERI seNsU strICto, BORRELIA AfZELII ANd BORRELIA gARINII As ANtIGeNs for seroloGICAl dIAGNosIs of lyMe borrelIosIs iva christova, iva trifonova, teodora Gladnishka, evgenia taseva, Vladislava ivanova, Dobrinka Rusimova National Center of Infectious and Parasitic Diseases, National Reference Tick-Borne Infections Laboratory, Sofia, Bulgaria correspondence to: iva christova e-mail: iva_christova@yahoo.com elIsA tests in-house eliSA tests were developed based on the synthesized peptides used as antigens. eliSA plates were coated overnight at 4 °c with the peptides at a concentration of 5 µg/ml. After a washing step, serum samples from patients were added at 1:200 dilution and incubated for 1 h at 37 °c. After an additional washing step, horseradish peroxidase-conjugated anti-human serum (DAKo, Dakopatts, Denmark) was added to the wells of the eliSA plate and the plate was again incubated for another 1 h at 37 °c. the antigen-antibody reaction was revealed by peroxidase substrate system (oPD and hydrogen peroxide) and optical density was measured at 450 nm. the cut-off value was calculated as 3 SD above the mean optical density of sera from 10 healthy blood donors tested at the same run.
AbstrACt
serum panels
Two different serum panels were tested. The first one consisted of serum samples from Bulgarian patients with lyme borreliosis: 50 sera from patients with erythema migrans (clinical hallmark of early Lyme borreliosis, not always serologically confirmed), 20 sera from patients with neuroborreliosis, and 10 sera from patients with Lyme arthritis. The first serum panel was used to analyse the sensitivity of the tests. the second serum panel was designed to test the specificity of the developed peptide eliSA tests. it contained 40 serum samples from patients with diseases known to give false-positive serological results when tested for lyme borreliosis: patients with syphilis (n = 10), leptospirosis (n = 10), rheumatoid arthritis (n = 10), and sclerodermia (n = 10).
results and discussion
Four different peptide eliSA tests were developed based on iR6 regions of two B. burgdorferi sensu stricto strains (B31 and 297), one B. afzelii (Pt7) and one B. garinii (iP90) strain. Serum samples from patients with various manifestations of lyme borreliosis were tested in order to reveal the applicability of such antigens. The Test specificity was assayed by reactivity with sera from other than lyme borreliosis diseases, all of which are already well-known to give false-positive results.
test results are shown in table 1. the two c6 peptides from B. burgdorferi sensu stricto showed higher reactivity than the c6 peptides from B. afzelii and B. garinii with sera from patients with early lyme borreliosis (erythema migrans) as well as from patients with lyme arthritis (disseminated lyme borreliosis). however, the c6 peptide from B. garinii appeared to be more reactive with sera from patients with neuroborreliosis. interestingly, the two peptides from B. burgdorferi sensu stricto showed different reactivity with sera from patients with erythema migrans (table 1).
The non-specific reactivity of peptide antigens was tested with sera from 40 patients with syphilis, leptospirosis, rheumatoid arthritis and sclerodermia. the c6 peptide from B. afzelii showed the lowest level of specificity (87.5 %), the c6 peptides from B. burgdorferi s.s. showed higher specificity (90 % and 92.5 %), and the c6 from B. garinii, the highest one (100 %). Overall, the specificity of the 4 peptides was high.
iR6 (c6) peptides have been tested by eliSA in the U.S.A. and Europe, but studies have shown significant differences in the sensitivity of the tests (1, 6) . According to some authors, the sensitivity is high in all stages of infection. According to others, the sensitivity is insufficient and recombinant VlsE antigen detects more antibodies than c6.
in order to test the applicability of the c6 peptide for serological diagnosis, we developed peptide eliSA tests for detection of antibodies in Lyme borreliosis, for the first time in Bulgaria. Peptide antigens from iR6 (c6) regions of Vlse proteins from the 3 main Borrelia species causing lyme disease in europe were tested.
this study showed that c6 peptides can be used successfully for diagnosis, since up to 80 % of the patients with early lyme borreliosis and neuroborreliosis and all patients with lyme arthritis could be diagnosed by the peptide eliSA tests. in addition, the overall specificity of the tests based on the C6 peptides was also high (87.5 % to 100 %). Moreover, the tests are easy to implement and very cheap, which is essential, since the antigens used contain only 26 amino acids and their synthesis is much more economically advantageous than the production of recombinant protein antigens.
the data obtained showed that the c6 peptides from B. burgdorferi sensu stricto detected the specific antibodies more often than the other c6 peptides in patients with early lyme disease from Bulgaria. Such finding for sera from the U.S.A. would not be surprising due to the well-known prevalence of B. burgdorferi sensu stricto in the United States. in europe, the other two Borrelia species (B. garinii and B. afzelii) are usually dominant. our studies on the infectivity of Bulgarian ticks have shown that they are mostly infected with B. afzelii, followed by B. burgdorferi sensu stricto and B. garinii (3) . this discrepancy between abundant B. afzelii in our ticks and predominant B. burgdorferi sensu stricto reactivity of the sera from patients with lyme borreliosis in Bulgaria could be explained by a hypothesis about different pathogenic potential of the different Borrelia species. the higher prevalence of B. afzelii in ticks but lower infectivity rate in patients could be explained by plausible lower pathogenic potential of B. afzelii in comparison with B. burgdorferi sensu stricto. it has been found that different Borrelia species are attributed to certain clinical manifestations: neuroborreliosis is associated with B. garinii and lyme arthritis is associated with B. burgdorferi sensu stricto (2) . this is most probably the reason of the higher reactivity of sera from patients with neuroborreliosis with the c6 peptide from B. garinii and the sera from lyme arthritis with the c6 from B. burgdorferi sensu stricto.
Conclusions
The analysis of the findings from this study showed a high reactivity of the c6 peptides, which is consistent with the high immunogenicity of this part of the Vlse antigen. the higher reactivity of the c6 from B. burgdorferi sensu stricto than those of c6 from B. garinii and B. afzelii supports our hypothesis for different pathogenic potential of Borrelia species.
the differences in the reactivity to the c6 peptides from different Borrelia species are in contrast to the conventional assumption that the c6 part of the protein chain of Vlse is highly conservative. Rather, it appears that c6 peptides from various borreliae lead to different results. the c6 eliSA tests are highly suitable for routine serological diagnosis of lyme borreliosis. they are very sensitive in various stages of the disease, cheap and easy to implement.
